These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6221689)

  • 21. Experiences on the efficacy and safety of nalidixic acid, oxolinic acid, cinoxacin and norfloxacin in the treatment of urinary tract infections (UTI).
    Sabbour MS; El Bokl MA; Osman LM
    Infection; 1984; 12(6):377-80. PubMed ID: 6240470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.
    Darrell RW; Modak SM; Fox CL
    Trans Am Ophthalmol Soc; 1984; 82():75-91. PubMed ID: 6242083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.
    Gu M; Zhang N; Zhang L; Xiong M; Yang Y; Gu X; Shen X; Ding H
    BMC Vet Res; 2015 Jul; 11():169. PubMed ID: 26209108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.
    Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH
    Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pefloxacin in rabbits: protein binding, extravascular diffusion, urinary excretion and bactericidal effect in experimental endocarditis.
    Contrepois A; Daldoss C; Pangon B; Garaud JJ; Kecir M; Sarrazin C; Vallois JM; Carbon C
    J Antimicrob Chemother; 1984 Jul; 14(1):51-7. PubMed ID: 6384175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics and tissue penetration of norfloxacin.
    Adhami ZN; Wise R; Weston D; Crump B
    J Antimicrob Chemother; 1984 Jan; 13(1):87-92. PubMed ID: 6230344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.
    Lucet JC; Herrmann M; Rohner P; Auckenthaler R; Waldvogel FA; Lew DP
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2312-7. PubMed ID: 2128441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
    Neu HC; Labthavikul P
    Antimicrob Agents Chemother; 1982 Jul; 22(1):23-7. PubMed ID: 6214995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of trimethoprim-sulfadoxine against Escherichia coli in a tissue cage model in calves.
    Greko C; Bengtsson B; Franklin A; Jacobsson SO; Wiese B; Luthman J
    J Vet Pharmacol Ther; 2002 Dec; 25(6):413-23. PubMed ID: 12485347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
    Ito A; Hirai K; Inoue M; Koga H; Suzue S; Irikura T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Norfloxacin sensitivity of bacterial pathogens of urinary tract infections].
    Modde H
    Schweiz Rundsch Med Prax; 1985 Apr; 74(17):439-42. PubMed ID: 3159064
    [No Abstract]   [Full Text] [Related]  

  • 32. Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.
    Hofbauer H; Naber KG; Kinzig-Schippers M; Sörgel F; Rustige-Wiedemann C; Wiedemann B; Reiz A; Kresken M
    Infection; 1997; 25(2):121-6. PubMed ID: 9108190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic studies of norfloxacin in laboratory animals.
    Gilfillan EC; Pelak BA; Bland JA; Malatesta PF; Gadebusch HH
    Chemotherapy; 1984; 30(5):288-96. PubMed ID: 6237890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
    Shah PM; Ottrad M; Stille W
    Eur J Clin Microbiol; 1983 Jun; 2(3):272-4. PubMed ID: 6224688
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norfloxacin for the treatment of uncomplicated urinary tract infections.
    Bailey RR; Peddie BA; Blake E
    N Z Med J; 1983 Jun; 96(733):446. PubMed ID: 6222277
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Muytjens HL; van der Ros-van de Repe J; van Veldhuizen G
    Antimicrob Agents Chemother; 1983 Aug; 24(2):302-4. PubMed ID: 6227281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
    Odenholt-Tornqvist I
    Scand J Infect Dis Suppl; 1989; 58():1-55. PubMed ID: 2499924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.